Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also contributes to disease progression and cardiovascular disease. Although the benefits of weight loss in the prevention of diabetes and as a critic...
Saved in:
Published in | Diabetes care Vol. 38; no. 6; pp. 1161 - 1172 |
---|---|
Main Authors | , |
Format | Journal Article Web Resource |
Language | English |
Published |
United States
American Diabetes Association
01.06.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also contributes to disease progression and cardiovascular disease. Although the benefits of weight loss in the prevention of diabetes and as a critical component of managing the condition are well established, weight reduction remains challenging for individuals with type 2 diabetes due to a host of metabolic and psychological factors. For many patients, lifestyle intervention is not enough to achieve weight loss, and alternative options, such as pharmacotherapy, need to be considered. However, many traditional glucose-lowering medications may lead to weight gain. This article focuses on the potential of currently available pharmacological strategies and on emerging approaches in development to support the glycemic and weight-loss goals of individuals with type 2 diabetes. Two pharmacotherapy types are considered: those developed primarily for blood glucose control that have a favorable effect on body weight and those developed primarily to induce weight loss that have a favorable effect on blood glucose control. Finally, the potential of combination therapies for the management of obese patients with type 2 diabetes is discussed. |
---|---|
AbstractList | Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also contributes to disease progression and cardiovascular disease. Although the benefits of weight loss in the prevention of diabetes and as a critical component of managing the condition are well established, weight reduction remains challenging for individuals with type 2 diabetes due to a host of metabolic and psychological factors. For many patients, lifestyle intervention is not enough to achieve weight loss, and alternative options, such as pharmacotherapy, need to be considered. However, many traditional glucose-lowering medications may lead to weight gain. This article focuses on the potential of currently available pharmacological strategies and on emerging approaches in development to support the glycemic and weight-loss goals of individuals with type 2 diabetes. Two pharmacotherapy types are considered: those developed primarily for blood glucose control that have a favorable effect on body weight and those developed primarily to induce weight loss that have a favorable effect on blood glucose control. Finally, the potential of combination therapies for the management of obese patients with type 2 diabetes is discussed. Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also contributes to disease progression and cardiovascular disease. Although the benefits of weight loss in the prevention of diabetes and as a critical component of managing the condition are well established, weight reduction remains challenging for individuals with type 2 diabetes due to a host of metabolic and psychological factors. For many patients, lifestyle intervention is not enough to achieve weight loss, and alternative options, such as pharmacotherapy, need to be considered. However, many traditional glucose-lowering medications may lead to weight gain. This article focuses on the potential of currently available pharmacological strategies and on emerging approaches in development to support the glycemic and weight-loss goals of individuals with type 2 diabetes. Two pharmacotherapy types are considered: those developed primarily for blood glucose control that have a favorable effect on body weight and those developed primarily to induce weight loss that have a favorable effect on blood glucose control. Finally, the potential of combination therapies for the management of obese patients with type 2 diabetes is discussed. 111 references |
Author | Scheen, André Van Gaal, Luc |
Author_xml | – sequence: 1 givenname: Luc surname: Van Gaal fullname: Van Gaal, Luc organization: Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium – sequence: 2 givenname: André surname: Scheen fullname: Scheen, André organization: Department of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, University of Liège, Liège, Belgium |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25998297$$D View this record in MEDLINE/PubMed |
BookMark | eNptkU1v1DAQhi1URLeFA38AWeJCD6H-SmJzq5aWIhUhoUUcrUk8SV0lzmI7SP33TbQth6qnGc0872hm3hNyFKaAhLzn7LOQsj53LVcFryR7RTbcyLIoS6WPyIZxZYrSGHFMTlK6Y4wppfUbciyWoham3pBff9D3t5n-gAA9jhgy9YHu7vdIBf3qocGM6QvdzjGuPQiOXo4Yex96erHfxwnaW0w0T3QXEfI64C153cGQ8N1jPCW_ry532-vi5ue379uLmwJUbXJRgzCKQwWdaZVrRNd0AmvdtshkCU52QtYOpO601KKSypWlhNqgcLwGVzp5SuRh7uCxRzvFxtt_wk7gD_k89BZa26AVotKWayE5W1SfDqpl978zpmxHn1ocBgg4zcnymolKqYqVC_rxGXo3zTEsN1le6UpzaVi1UB8eqbkZ0dl99CPEe_v04wU4OwBtnFKK2P1HOLOrf3b1z67-Lez5M7b1GbKfQo7ghxcUD1tQmi8 |
CODEN | DICAD2 |
CitedBy_id | crossref_primary_10_1016_S2213_8587_17_30092_X crossref_primary_10_1097_01_NUMA_0000491124_22612_0e crossref_primary_10_1080_14656566_2020_1729123 crossref_primary_10_1080_17425255_2018_1418325 crossref_primary_10_1016_j_jad_2021_11_020 crossref_primary_10_1111_dom_12657 crossref_primary_10_1111_dom_12932 crossref_primary_10_2337_dc22_S008 crossref_primary_10_1111_jdi_12810 crossref_primary_10_3390_nu14204325 crossref_primary_10_1038_nutd_2017_32 crossref_primary_10_1038_s41574_018_0118_x crossref_primary_10_5812_ircmj_64581 crossref_primary_10_1016_j_diabres_2022_109900 crossref_primary_10_1016_j_jaim_2023_100768 crossref_primary_10_1016_j_med_2016_09_010 crossref_primary_10_1007_s00125_019_05065_8 crossref_primary_10_2337_dc23_S008 crossref_primary_10_1159_000480525 crossref_primary_10_3389_fendo_2017_00381 crossref_primary_10_3390_nu14183784 crossref_primary_10_2337_dc20_S008 crossref_primary_10_1186_s13643_020_01467_7 crossref_primary_10_1007_s11892_019_1236_0 crossref_primary_10_3389_fendo_2018_00634 crossref_primary_10_1007_s40265_017_0783_4 crossref_primary_10_1002_jssc_201600924 crossref_primary_10_1007_s40618_017_0719_6 crossref_primary_10_1111_jdi_12800 crossref_primary_10_1016_j_jcjd_2019_06_004 crossref_primary_10_1111_dom_12660 crossref_primary_10_3389_fcdhc_2022_1044005 crossref_primary_10_2215_CJN_07670715 crossref_primary_10_3390_nu14112299 crossref_primary_10_1016_j_cnur_2021_07_008 crossref_primary_10_1016_j_pec_2020_05_015 crossref_primary_10_1016_j_fochx_2022_100222 crossref_primary_10_1007_s12020_020_02396_0 crossref_primary_10_1055_a_2078_9491 crossref_primary_10_1007_s13300_024_01615_5 crossref_primary_10_3390_nu12092749 crossref_primary_10_1080_17512433_2017_1376652 crossref_primary_10_7762_cnr_2015_4_3_201 crossref_primary_10_1186_s12933_020_0990_2 crossref_primary_10_3389_fendo_2022_1094954 crossref_primary_10_1016_j_numecd_2023_05_024 crossref_primary_10_1161_CIR_0000000000000766 crossref_primary_10_1016_j_dsx_2016_12_026 crossref_primary_10_2337_dc18_1667 crossref_primary_10_1016_j_metabol_2019_03_007 crossref_primary_10_1016_j_pcd_2021_09_005 crossref_primary_10_4103_ym_ym_57_24 crossref_primary_10_1111_jdi_13125 crossref_primary_10_1038_nrendo_2016_86 crossref_primary_10_1038_s41574_018_0002_8 crossref_primary_10_1002_oby_21700 crossref_primary_10_1016_j_nursi_2016_11_008 crossref_primary_10_4158_EP_2018_0444 crossref_primary_10_1177_2165079920986160 crossref_primary_10_1080_00325481_2016_1169894 crossref_primary_10_1007_s40265_017_0801_6 crossref_primary_10_37376_jsh_vi71_5728 crossref_primary_10_1016_j_pcd_2022_02_002 crossref_primary_10_2337_dc22_2170 crossref_primary_10_1155_2018_1682959 crossref_primary_10_1186_s44263_024_00095_w crossref_primary_10_23736_S2724_6507_23_04103_9 crossref_primary_10_58931_cdet_2023_115 crossref_primary_10_1080_2331205X_2019_1639880 crossref_primary_10_3390_ijms25031882 crossref_primary_10_1111_dom_16201 crossref_primary_10_1007_s10068_017_0223_y crossref_primary_10_1111_dom_13573 crossref_primary_10_1111_bjd_17741 crossref_primary_10_2337_dcS15_3016 crossref_primary_10_1097_01_NURSE_0000480595_99521_56 crossref_primary_10_1186_s12937_023_00909_x crossref_primary_10_1016_j_numecd_2016_11_124 crossref_primary_10_3390_microorganisms8081246 crossref_primary_10_1177_0884533617713189 crossref_primary_10_1016_j_lfs_2022_120543 crossref_primary_10_1016_j_biopha_2023_114582 crossref_primary_10_1016_j_pcd_2020_05_004 crossref_primary_10_5322_JESI_2020_29_4_351 crossref_primary_10_1080_13696998_2024_2316400 crossref_primary_10_1016_j_deman_2021_100005 crossref_primary_10_18553_jmcp_2019_18321 crossref_primary_10_24927_rce2024_006 crossref_primary_10_1007_s13300_019_0645_z crossref_primary_10_1080_14656566_2017_1297424 crossref_primary_10_1007_s13300_023_01511_4 crossref_primary_10_1002_oby_21883 crossref_primary_10_2147_VHRM_S345810 crossref_primary_10_1093_bjsopen_zrad077 crossref_primary_10_1136_bmjdrc_2021_002136 crossref_primary_10_3111_13696998_2015_1069297 crossref_primary_10_1007_s13679_020_00419_5 crossref_primary_10_3390_ijms23158365 crossref_primary_10_1016_j_nutres_2018_05_005 crossref_primary_10_1080_00325481_2016_1210988 crossref_primary_10_1097_MD_0000000000003462 crossref_primary_10_1007_s11892_016_0789_4 crossref_primary_10_1186_s13063_021_05442_y crossref_primary_10_1007_s13300_017_0343_7 crossref_primary_10_3390_fermentation9030254 crossref_primary_10_1007_s40265_020_01393_x crossref_primary_10_1038_s41366_022_01217_w crossref_primary_10_15406_mojddt_2017_01_00005 crossref_primary_10_2337_dc25_S008 crossref_primary_10_1002_dmrr_3099 crossref_primary_10_2337_ds17_0045 crossref_primary_10_1007_s11695_020_05075_1 crossref_primary_10_12968_npre_2017_15_7_338 crossref_primary_10_1016_j_mmm_2021_10_012 crossref_primary_10_1080_13543784_2016_1221925 crossref_primary_10_1016_j_clinthera_2017_03_013 crossref_primary_10_1093_cdn_nzz067 crossref_primary_10_1016_j_jdiacomp_2017_06_004 crossref_primary_10_1155_2018_9264204 crossref_primary_10_36290_vnl_2020_128 crossref_primary_10_1371_journal_pone_0282143 crossref_primary_10_2337_dc15_0875 crossref_primary_10_1586_17512433_2016_1141046 crossref_primary_10_1155_2020_9327910 crossref_primary_10_1177_1934578X241259377 crossref_primary_10_2174_011871529X326042241031060350 crossref_primary_10_1007_s11892_017_0894_z crossref_primary_10_1016_j_clinthera_2019_01_001 crossref_primary_10_3803_EnM_2019_34_3_247 crossref_primary_10_1186_s13098_019_0400_7 crossref_primary_10_1177_2047487317709369 crossref_primary_10_1080_10408398_2021_1873732 crossref_primary_10_2337_dc18_2270 crossref_primary_10_1186_s12889_020_09231_1 crossref_primary_10_1016_j_diabres_2016_04_033 crossref_primary_10_1371_journal_pone_0292553 crossref_primary_10_4163_jnh_2023_56_1_24 crossref_primary_10_3390_nu15173693 crossref_primary_10_3390_nu16020329 crossref_primary_10_1016_S1957_2557_18_30043_9 crossref_primary_10_1016_j_jaim_2017_03_005 crossref_primary_10_1016_j_ejphar_2016_11_028 crossref_primary_10_1111_dom_14745 crossref_primary_10_1111_dom_13658 crossref_primary_10_2174_1573399814666180403164529 crossref_primary_10_1517_14740338_2015_1100167 crossref_primary_10_1007_s13669_015_0129_8 crossref_primary_10_1016_j_tvir_2020_100654 crossref_primary_10_1111_dom_14221 crossref_primary_10_2337_dc21_S008 crossref_primary_10_1002_dmrr_2981 crossref_primary_10_1038_nrendo_2016_51 crossref_primary_10_2337_dc24_S008 crossref_primary_10_1007_s11684_021_0873_2 crossref_primary_10_1136_bmjopen_2020_038970 crossref_primary_10_1093_advances_nmz002 crossref_primary_10_1097_NHH_0000000000000576 crossref_primary_10_1007_s13340_018_0345_3 crossref_primary_10_3390_ijms25042324 |
Cites_doi | 10.2337/diacare.22.7.1137 10.2337/dc14-2441 10.1002/oby.20356 10.1177/2040622313506730 10.2337/db13-0710 10.1152/ajpregu.00495.2013 10.1038/oby.2012.59 10.1111/j.1463-1326.2009.01059.x 10.1056/NEJMoa012512 10.1002/oby.20662 10.1016/S0140-6736(13)62154-6 10.1111/j.1464-5491.2004.01474.x 10.2337/dc11-0931 10.1002/dmrr.2479 10.1001/archinternmed.2009.266 10.1002/oby.20663 10.1001/jama.2012.9931 10.2337/dc13-0234 10.1007/BF02576216 10.1016/S0140-6736(11)60205-5 10.1210/jcem.87.6.8567 10.1007/s40265-014-0337-y 10.1111/dom.12083 10.3945/ajcn.2009.28449B 10.1016/0167-4889(94)00237-9 10.1038/nrendo.2013.113 10.1016/j.diabet.2007.01.003 10.1007/s00592-013-0489-3 10.3109/07853890.2010.541490 10.2337/diabetes.50.1.105 10.1056/NEJMra041001 10.1097/MED.0b013e32835edb32 10.1038/sj.ijo.0802783 10.1016/j.amjcard.2005.03.053 10.2337/diacare.28.6.1526 10.2337/dc13-2338 10.2337/diacare.11.7.567 10.1111/dom.12054 10.1093/ajhp/62.2.173 10.2337/dc12-2462 10.2337/dc12-1391 10.1093/eurpub/ckl262 10.1517/14712598.2011.619974 10.2337/dc13-1928 10.1111/j.1365-2710.2011.01280.x 10.1111/j.1742-1241.2009.02265.x 10.2165/00002018-200730120-00005 10.1111/j.1463-1326.2009.01075.x 10.2174/1389201015666140915150312 10.7326/0003-4819-154-2-201101180-00300 10.1186/1471-2458-9-88 10.1016/S0140-6736(09)60659-0 10.1056/NEJMp1314078 10.1186/1472-6823-13-58 10.1111/j.1463-1326.2012.01556.x 10.1586/eem.12.51 10.1038/282503a0 10.1159/000103273 10.1152/ajpregu.00755.2010 10.3810/pgm.2014.05.2753 10.1016/S0140-6736(02)07952-7 10.1016/S2213-8587(14)70004-X 10.1210/jcem.82.12.4460 10.1111/j.1742-1241.2012.03006.x 10.1111/j.1463-1326.2009.01158.x 10.1007/s001250051172 10.1016/S0140-6736(09)61375-1 10.1111/dom.12307 10.1111/j.1463-1326.2010.01337.x 10.1097/MED.0b013e328357f0e0 10.2337/dc10-2415 10.1111/j.1463-1326.2008.00970.x 10.3945/ajcn.111.024927 10.1038/nm.3761 10.1210/jc.2011-2260 10.2174/187221411797265917 10.1185/03007995.2012.684044 10.1056/NEJMoa1105816 10.2337/dc09-1203 10.1242/dmm.009621 10.1111/dom.12189 10.2337/diacare.27.1.155 10.1185/03007995.2013.850066 10.2337/db13-1609 10.1038/nchembio.209 10.1056/NEJMoa0909809 10.1517/14656566.2011.581663 10.1038/oby.2012.66 10.1111/j.1463-1326.2006.00686.x 10.1038/ijo.2011.158 10.1016/S0140-6736(98)07019-6 10.2337/dc06-2001 10.1111/dom.12048 10.1007/s00125-011-2332-0 10.1038/nrendo.2009.48 10.1185/03007995.2011.590127 10.1038/nature05487 10.1369/jhc.2008.951319 10.2337/dc14-0930 10.1111/j.1463-1326.2012.01673.x 10.1111/j.1742-1241.2006.01128.x |
ContentType | Journal Article Web Resource |
Copyright | 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. Copyright American Diabetes Association Jun 2015 |
Copyright_xml | – notice: 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. – notice: Copyright American Diabetes Association Jun 2015 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ ASE FPQ K6X Q33 |
DOI | 10.2337/dc14-1630 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium British Nursing Index British Nursing Index (BNI) (1985 to Present) British Nursing Index Université de Liège - Open Repository and Bibliography (ORBI) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium British Nursing Index |
DatabaseTitleList | MEDLINE British Nursing Index ProQuest Health & Medical Complete (Alumni) CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1935-5548 |
EndPage | 1172 |
ExternalDocumentID | oai_orbi_ulg_ac_be_2268_182310 3708747661 25998297 10_2337_dc14_1630 |
Genre | Research Support, Non-U.S. Gov't Journal Article Review Feature |
GroupedDBID | --- -ET ..I .XZ 08P 0R~ 18M 29F 2WC 4.4 53G 5GY 5RE 5RS 5VS 6PF 8R4 8R5 AAFWJ AAIKC AAKAS AAMNW AAWTL AAYEP AAYXX ABOCM ABPPZ ACGFO ACGOD ADBBV ADZCM AEGXH AENEX AERZD AFOSN AFRAH AHMBA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BENPR BTFSW CITATION CS3 DIK DU5 E3Z EBS EDB EJD EMOBN EX3 F5P GX1 H13 HZ~ IAO IEA IHR INH INR IOF IPO KQ8 L7B M0K M5~ O5R O5S O9- OK1 OVD P2P PCD Q2X RHI SV3 TDI TEORI TR2 TWZ VVN W8F WH7 WOQ WOW YHG YOC ~KM .55 .GJ 3O- 41~ 7RV 7X2 7X7 88E 88I 8AF 8AO 8C1 8F7 8FE 8FH 8FI 8FJ 8G5 AAQOH AAQQT AAYJJ ABUWG AFFNX AFKRA AI. AN0 AQUVI ATCPS AZQEC BCR BCU BEC BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C1A CCPQU CGR CUY CVF DWQXO ECM EIF FYUFA GNUQQ GUQSH HCIFZ HMCUK IAG ITC J5H K9- M0R M0T M1P M2O M2P M2Q N4W NAPCQ NPM PEA PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO S0X SJFOW UKHRP VH1 WHG X7M ZCG ZGI ZXP K9. ASE FPQ K6X Q33 |
ID | FETCH-LOGICAL-a479t-7a2941a6af9c4db2fbf2e78cce035ad3f237da38f8382634d553a79e2d17ad5d3 |
ISSN | 0149-5992 1935-5548 |
IngestDate | Fri Jul 25 15:26:15 EDT 2025 Fri Jul 11 10:03:45 EDT 2025 Mon Jun 30 16:58:02 EDT 2025 Mon Jul 21 05:53:57 EDT 2025 Thu Apr 24 22:57:08 EDT 2025 Tue Jul 01 04:11:46 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
License | 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-a479t-7a2941a6af9c4db2fbf2e78cce035ad3f237da38f8382634d553a79e2d17ad5d3 |
Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-2 content type line 23 scopus-id:2-s2.0-84940559645 |
PMID | 25998297 |
PQID | 1686813906 |
PQPubID | 47715 |
PageCount | 12 |
ParticipantIDs | liege_orbi_v2_oai_orbi_ulg_ac_be_2268_182310 proquest_miscellaneous_1702644605 proquest_journals_1686813906 pubmed_primary_25998297 crossref_primary_10_2337_dc14_1630 crossref_citationtrail_10_2337_dc14_1630 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-06-01 |
PublicationDateYYYYMMDD | 2015-06-01 |
PublicationDate_xml | – month: 06 year: 2015 text: 2015-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Alexandria |
PublicationTitle | Diabetes care |
PublicationTitleAlternate | Diabetes Care |
PublicationYear | 2015 |
Publisher | American Diabetes Association |
Publisher_xml | – name: American Diabetes Association |
References | Wing (2022031301280987800_B7) 2010; 170 Göke (2022031301280987800_B36) 1993; 193 Fadini (2022031301280987800_B49) 2013; 50 Wilding (2022031301280987800_B34) 2006; 60 Kahn (2022031301280987800_B105) 2014; 383 Rueda-Clausen (2022031301280987800_B78) 2013; 9 Ferrannini (2022031301280987800_B64) 2014; 57 Toft-Nielsen (2022031301280987800_B40) 1999; 22 Devenny (2022031301280987800_B63) 2012; 20 2022031301280987800_B3 Egan (2022031301280987800_B54) 2014; 370 Day (2022031301280987800_B109) 2009; 5 Van Gaal (2022031301280987800_B2) 2006; 444 Wing (2022031301280987800_B8) 2011; 34 Rosenstock (2022031301280987800_B82) 2007; 30 Buse (2022031301280987800_B48) 2009; 374 Guh (2022031301280987800_B4) 2009; 9 Kolterman (2022031301280987800_B41) 2005; 62 Cabrera (2022031301280987800_B15) 2012; 28 Zander (2022031301280987800_B38) 2002; 359 Samson (2022031301280987800_B53) 2013; 20 Dushay (2022031301280987800_B44) 2012; 35 2022031301280987800_B45 O’Neil (2022031301280987800_B71) 2012; 20 Katsiki (2022031301280987800_B86) 2011; 43 Liebl (2022031301280987800_B26) 2009; 11 Sumithran (2022031301280987800_B20) 2011; 365 Kliewer (2022031301280987800_B107) 2010; 91 Jendle (2022031301280987800_B89) 2009; 11 Gadde (2022031301280987800_B80) 2011; 377 Knowler (2022031301280987800_B6) 2002; 346 Jacob (2022031301280987800_B77) 2009; 11 Cummings (2022031301280987800_B97) 2013; 15 Younk (2022031301280987800_B68) 2011; 12 Liakos (2022031301280987800_B67) 2014; 16 Woods (2022031301280987800_B27) 1979; 282 Rosenbaum (2022031301280987800_B22) 2008; 118 Tornehave (2022031301280987800_B37) 2008; 56 Pi-Sunyer (2022031301280987800_B12) 2005; 28 Bolinder (2022031301280987800_B58) 2014; 16 2022031301280987800_B103 Rubin (2022031301280987800_B9) 2014; 37 Russell-Jones (2022031301280987800_B25) 2007; 9 Clemmensen (2022031301280987800_B102) 2014; 63 Toft (2022031301280987800_B17) 2007; 17 Maclean (2022031301280987800_B19) 2011; 301 Hiatt (2022031301280987800_B90) 2012; 308 Blonde (2022031301280987800_B51) 2009; 11 Cai (2022031301280987800_B28) 2001; 50 Lovshin (2022031301280987800_B98) 2009; 5 Rodgers (2022031301280987800_B74) 2012; 5 Singh-Franco (2022031301280987800_B69) 2011; 13 Berne (2022031301280987800_B70) 2005; 22 Grasso (2022031301280987800_B99) 2011; 5 Esposito (2022031301280987800_B43) 2011; 27 Niswender (2022031301280987800_B47) 2013; 15 Tatarkiewicz (2022031301280987800_B42) 2014; 306 UK Prospective Diabetes Study (UKPDS) Group (2022031301280987800_B13) 1998; 352 De Block (2022031301280987800_B46) 2012; 7 van Dieren (2022031301280987800_B24) 2012; 14 Riddle (2022031301280987800_B96) 2013; 36 de Luis (2022031301280987800_B21) 2007; 51 Buse (2022031301280987800_B94) 2011; 154 Van Gaal (2022031301280987800_B1) 2012; 19 Hermansen (2022031301280987800_B32) 2007; 30 Inzucchi (2022031301280987800_B5) 2015; 38 Pencek (2022031301280987800_B52) 2012; 66 Berhan (2022031301280987800_B66) 2013; 13 Wilding (2022031301280987800_B81) 2004; 28 Foster (2022031301280987800_B10) 2009; 169 Yki-Järvinen (2022031301280987800_B29) 1997; 82 Bays (2022031301280987800_B61) 2014; 22 Hollander (2022031301280987800_B73) 2013; 36 Hughes (2022031301280987800_B110) 2013; 21 Astrup (2022031301280987800_B88) 2012; 36 Omar (2022031301280987800_B108) 2014; 63 Garvey (2022031301280987800_B72) 2014; 37 Garvey (2022031301280987800_B84) 2012; 95 Scheen (2022031301280987800_B55) 2015; 75 Bolinder (2022031301280987800_B57) 2012; 97 Buse (2022031301280987800_B95) 2013; 62 Mäkimattila (2022031301280987800_B31) 1999; 42 Stenlöf (2022031301280987800_B59) 2013; 15 Scheen (2022031301280987800_B16) 2007; 33 Fonseca (2022031301280987800_B14) 2013; 36 Eriksson (2022031301280987800_B30) 1995; 1266 Perkins (2022031301280987800_B65) 2014; 37 Tam (2022031301280987800_B101) 2011; 11 Willms (2022031301280987800_B39) 1996; 81 Derosa (2022031301280987800_B75) 2012; 37 Rosenstock (2022031301280987800_B92) 2010; 33 2022031301280987800_B85 Miyazaki (2022031301280987800_B35) 2002; 87 Tonstad (2022031301280987800_B83) 2005; 96 Moon (2022031301280987800_B100) 2012; 55 Araujo (2022031301280987800_B93) 2014; 15 Torgerson (2022031301280987800_B76) 2004; 27 Smith (2022031301280987800_B79) 2010; 363 Yki-Järvinen (2022031301280987800_B33) 2004; 351 Scheen (2022031301280987800_B23) 2014; 2 Gallwitz (2022031301280987800_B50) 2010; 64 2022031301280987800_B91 Stenlöf (2022031301280987800_B60) 2014; 30 Look AHEAD Research Group (2022031301280987800_B11) 2014; 22 The DCCT Research Group (2022031301280987800_B18) 1988; 11 Usiskin (2022031301280987800_B62) 2014; 126 Astrup (2022031301280987800_B87) 2009; 374 Finan (2022031301280987800_B104) 2015; 21 Meneghini (2022031301280987800_B111) 2013; 15 Zhang (2022031301280987800_B56) 2014; 30 Troke (2022031301280987800_B106) 2014; 5 |
References_xml | – volume: 22 start-page: 1137 year: 1999 ident: 2022031301280987800_B40 article-title: Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients publication-title: Diabetes Care doi: 10.2337/diacare.22.7.1137 – volume: 38 start-page: 140 year: 2015 ident: 2022031301280987800_B5 article-title: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes publication-title: Diabetes Care doi: 10.2337/dc14-2441 – volume: 21 start-page: 1782 year: 2013 ident: 2022031301280987800_B110 article-title: Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women publication-title: Obesity (Silver Spring) doi: 10.1002/oby.20356 – volume: 5 start-page: 4 year: 2014 ident: 2022031301280987800_B106 article-title: The future role of gut hormones in the treatment of obesity publication-title: Ther Adv Chronic Dis doi: 10.1177/2040622313506730 – volume: 63 start-page: 101 year: 2014 ident: 2022031301280987800_B108 article-title: Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice publication-title: Diabetes doi: 10.2337/db13-0710 – volume: 306 start-page: R490 year: 2014 ident: 2022031301280987800_B42 article-title: Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor publication-title: Am J Physiol Regul Integr Comp Physiol doi: 10.1152/ajpregu.00495.2013 – volume: 20 start-page: 1645 year: 2012 ident: 2022031301280987800_B63 article-title: Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats publication-title: Obesity (Silver Spring) doi: 10.1038/oby.2012.59 – volume: 11 start-page: 1001 year: 2009 ident: 2022031301280987800_B26 article-title: A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2009.01059.x – volume: 346 start-page: 393 year: 2002 ident: 2022031301280987800_B6 article-title: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin publication-title: N Engl J Med doi: 10.1056/NEJMoa012512 – volume: 22 start-page: 5 year: 2014 ident: 2022031301280987800_B11 article-title: Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study publication-title: Obesity (Silver Spring) doi: 10.1002/oby.20662 – volume: 383 start-page: 1068 year: 2014 ident: 2022031301280987800_B105 article-title: Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future publication-title: Lancet doi: 10.1016/S0140-6736(13)62154-6 – volume: 22 start-page: 612 year: 2005 ident: 2022031301280987800_B70 article-title: A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin publication-title: Diabet Med doi: 10.1111/j.1464-5491.2004.01474.x – volume: 35 start-page: 4 year: 2012 ident: 2022031301280987800_B44 article-title: Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes publication-title: Diabetes Care doi: 10.2337/dc11-0931 – volume: 30 start-page: 204 year: 2014 ident: 2022031301280987800_B56 article-title: Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials publication-title: Diabetes Metab Res Rev doi: 10.1002/dmrr.2479 – volume: 169 start-page: 1619 year: 2009 ident: 2022031301280987800_B10 article-title: A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study publication-title: Arch Intern Med doi: 10.1001/archinternmed.2009.266 – volume: 22 start-page: 1042 year: 2014 ident: 2022031301280987800_B61 article-title: Canagliflozin: effects in overweight and obese subjects without diabetes mellitus publication-title: Obesity (Silver Spring) doi: 10.1002/oby.20663 – volume: 308 start-page: 1099 year: 2012 ident: 2022031301280987800_B90 article-title: Cardiovascular risk assessment in the development of new drugs for obesity publication-title: JAMA doi: 10.1001/jama.2012.9931 – volume: 36 start-page: 4022 year: 2013 ident: 2022031301280987800_B73 article-title: Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc13-0234 – volume: 118 start-page: 2583 year: 2008 ident: 2022031301280987800_B22 article-title: Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli publication-title: J Clin Invest – volume: 193 start-page: 97 year: 1993 ident: 2022031301280987800_B36 article-title: Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas publication-title: Res Exp Med (Berl) doi: 10.1007/BF02576216 – volume: 377 start-page: 1341 year: 2011 ident: 2022031301280987800_B80 article-title: Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(11)60205-5 – volume: 87 start-page: 2784 year: 2002 ident: 2022031301280987800_B35 article-title: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.87.6.8567 – volume: 75 start-page: 33 year: 2015 ident: 2022031301280987800_B55 article-title: Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus publication-title: Drugs doi: 10.1007/s40265-014-0337-y – volume: 170 start-page: 1566 year: 2010 ident: 2022031301280987800_B7 article-title: Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial publication-title: Arch Intern Med – volume: 15 start-page: 729 year: 2013 ident: 2022031301280987800_B111 article-title: Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes publication-title: Diabetes Obes Metab doi: 10.1111/dom.12083 – volume: 91 start-page: 254S year: 2010 ident: 2022031301280987800_B107 article-title: Fibroblast growth factor 21: from pharmacology to physiology publication-title: Am J Clin Nutr doi: 10.3945/ajcn.2009.28449B – volume: 81 start-page: 327 year: 1996 ident: 2022031301280987800_B39 article-title: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients publication-title: J Clin Endocrinol Metab – volume: 1266 start-page: 101 year: 1995 ident: 2022031301280987800_B30 article-title: Evidence for the key role of the adipocyte cGMP-inhibited cAMP phosphodiesterase in the antilipolytic action of insulin publication-title: Biochim Biophys Acta doi: 10.1016/0167-4889(94)00237-9 – volume: 9 start-page: 467 year: 2013 ident: 2022031301280987800_B78 article-title: New pharmacological approaches for obesity management publication-title: Nat Rev Endocrinol doi: 10.1038/nrendo.2013.113 – volume: 33 start-page: 169 year: 2007 ident: 2022031301280987800_B16 article-title: Abnormal glucose metabolism in patients treated with antipsychotics publication-title: Diabetes Metab doi: 10.1016/j.diabet.2007.01.003 – volume: 50 start-page: 943 year: 2013 ident: 2022031301280987800_B49 article-title: Independent glucose and weight-reducing effects of liraglutide in a real-world population of type 2 diabetic outpatients publication-title: Acta Diabetol doi: 10.1007/s00592-013-0489-3 – volume: 43 start-page: 249 year: 2011 ident: 2022031301280987800_B86 article-title: Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘a new kid on the block’ publication-title: Ann Med doi: 10.3109/07853890.2010.541490 – volume: 50 start-page: 105 year: 2001 ident: 2022031301280987800_B28 article-title: Hypoglycemia activates orexin neurons and selectively increases hypothalamic orexin-B levels: responses inhibited by feeding and possibly mediated by the nucleus of the solitary tract publication-title: Diabetes doi: 10.2337/diabetes.50.1.105 – volume: 351 start-page: 1106 year: 2004 ident: 2022031301280987800_B33 article-title: Thiazolidinediones publication-title: N Engl J Med doi: 10.1056/NEJMra041001 – ident: 2022031301280987800_B103 – volume: 20 start-page: 87 year: 2013 ident: 2022031301280987800_B53 article-title: GLP-1R agonist therapy for diabetes: benefits and potential risks publication-title: Curr Opin Endocrinol Diabetes Obes doi: 10.1097/MED.0b013e32835edb32 – volume: 28 start-page: 1399 year: 2004 ident: 2022031301280987800_B81 article-title: A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects publication-title: Int J Obes Relat Metab Disord doi: 10.1038/sj.ijo.0802783 – volume: 96 start-page: 243 year: 2005 ident: 2022031301280987800_B83 article-title: Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2005.03.053 – volume: 28 start-page: 1526 year: 2005 ident: 2022031301280987800_B12 article-title: Weight loss in type 2 diabetic patients publication-title: Diabetes Care doi: 10.2337/diacare.28.6.1526 – volume: 37 start-page: 1480 year: 2014 ident: 2022031301280987800_B65 article-title: Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial publication-title: Diabetes Care doi: 10.2337/dc13-2338 – volume: 11 start-page: 567 year: 1988 ident: 2022031301280987800_B18 article-title: Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial publication-title: Diabetes Care doi: 10.2337/diacare.11.7.567 – volume: 15 start-page: 372 year: 2013 ident: 2022031301280987800_B59 article-title: Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise publication-title: Diabetes Obes Metab doi: 10.1111/dom.12054 – volume: 62 start-page: 173 year: 2005 ident: 2022031301280987800_B41 article-title: Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus publication-title: Am J Health Syst Pharm doi: 10.1093/ajhp/62.2.173 – volume: 36 start-page: 2497 year: 2013 ident: 2022031301280987800_B96 article-title: Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) publication-title: Diabetes Care doi: 10.2337/dc12-2462 – volume: 36 start-page: 2162 year: 2013 ident: 2022031301280987800_B14 article-title: Determinants of weight gain in the action to control cardiovascular risk in diabetes trial publication-title: Diabetes Care doi: 10.2337/dc12-1391 – volume: 17 start-page: 455 year: 2007 ident: 2022031301280987800_B17 article-title: Diet and exercise intervention in a general population—mediators of participation and adherence: the Inter99 study publication-title: Eur J Public Health doi: 10.1093/eurpub/ckl262 – volume: 11 start-page: 1677 year: 2011 ident: 2022031301280987800_B101 article-title: Novel strategy for the use of leptin for obesity therapy publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.2011.619974 – volume: 37 start-page: 1544 year: 2014 ident: 2022031301280987800_B9 article-title: Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial publication-title: Diabetes Care doi: 10.2337/dc13-1928 – volume: 37 start-page: 187 year: 2012 ident: 2022031301280987800_B75 article-title: Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2011.01280.x – volume: 64 start-page: 267 year: 2010 ident: 2022031301280987800_B50 article-title: Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time publication-title: Int J Clin Pract doi: 10.1111/j.1742-1241.2009.02265.x – volume: 30 start-page: 1127 year: 2007 ident: 2022031301280987800_B32 article-title: Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus publication-title: Drug Saf doi: 10.2165/00002018-200730120-00005 – volume: 11 start-page: 26 year: 2009 ident: 2022031301280987800_B51 article-title: The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2009.01075.x – volume: 15 start-page: 609 year: 2014 ident: 2022031301280987800_B93 article-title: Antihyperglycemic potential of incretins orally delivered via nano and microsystems and subsequent glucoregulatory effects publication-title: Curr Pharm Biotechnol doi: 10.2174/1389201015666140915150312 – volume: 154 start-page: 103 year: 2011 ident: 2022031301280987800_B94 article-title: Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial publication-title: Ann Intern Med doi: 10.7326/0003-4819-154-2-201101180-00300 – volume: 9 start-page: 88 year: 2009 ident: 2022031301280987800_B4 article-title: The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis publication-title: BMC Public Health doi: 10.1186/1471-2458-9-88 – volume: 374 start-page: 39 year: 2009 ident: 2022031301280987800_B48 article-title: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) publication-title: Lancet doi: 10.1016/S0140-6736(09)60659-0 – volume: 370 start-page: 794 year: 2014 ident: 2022031301280987800_B54 article-title: Pancreatic safety of incretin-based drugs—FDA and EMA assessment publication-title: N Engl J Med doi: 10.1056/NEJMp1314078 – volume: 62 start-page: A16 year: 2013 ident: 2022031301280987800_B95 article-title: IDegLira, a novel fixed ratio combination of insulin degludec and liraglutide, is efficacious and safe in subjects with type 2 diabetes: a large, randomized phase 3 trial publication-title: Diabetes – volume: 13 start-page: 58 year: 2013 ident: 2022031301280987800_B66 article-title: Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials publication-title: BMC Endocr Disord doi: 10.1186/1472-6823-13-58 – volume: 14 start-page: 464 year: 2012 ident: 2022031301280987800_B24 article-title: Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2012.01556.x – volume: 7 start-page: 611 year: 2012 ident: 2022031301280987800_B46 article-title: Efficacy and safety of exenatide once weekly: an overview of the DURATION trials publication-title: Expert Rev Endocrinol Metab doi: 10.1586/eem.12.51 – volume: 282 start-page: 503 year: 1979 ident: 2022031301280987800_B27 article-title: Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons publication-title: Nature doi: 10.1038/282503a0 – volume: 51 start-page: 134 year: 2007 ident: 2022031301280987800_B21 article-title: Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects publication-title: Ann Nutr Metab doi: 10.1159/000103273 – volume: 301 start-page: R581 year: 2011 ident: 2022031301280987800_B19 article-title: Biology’s response to dieting: the impetus for weight regain publication-title: Am J Physiol Regul Integr Comp Physiol doi: 10.1152/ajpregu.00755.2010 – volume: 126 start-page: 16 year: 2014 ident: 2022031301280987800_B62 article-title: Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results publication-title: Postgrad Med doi: 10.3810/pgm.2014.05.2753 – volume: 359 start-page: 824 year: 2002 ident: 2022031301280987800_B38 article-title: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study publication-title: Lancet doi: 10.1016/S0140-6736(02)07952-7 – volume: 2 start-page: 911 year: 2014 ident: 2022031301280987800_B23 article-title: Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(14)70004-X – volume: 82 start-page: 4037 year: 1997 ident: 2022031301280987800_B29 article-title: Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.82.12.4460 – volume: 66 start-page: 1021 year: 2012 ident: 2022031301280987800_B52 article-title: Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations publication-title: Int J Clin Pract doi: 10.1111/j.1742-1241.2012.03006.x – volume: 11 start-page: 1163 year: 2009 ident: 2022031301280987800_B89 article-title: Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2009.01158.x – volume: 42 start-page: 406 year: 1999 ident: 2022031301280987800_B31 article-title: Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus publication-title: Diabetologia doi: 10.1007/s001250051172 – volume: 374 start-page: 1606 year: 2009 ident: 2022031301280987800_B87 article-title: Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study publication-title: Lancet doi: 10.1016/S0140-6736(09)61375-1 – volume: 16 start-page: 984 year: 2014 ident: 2022031301280987800_B67 article-title: Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis publication-title: Diabetes Obes Metab doi: 10.1111/dom.12307 – volume: 13 start-page: 169 year: 2011 ident: 2022031301280987800_B69 article-title: The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2010.01337.x – volume: 19 start-page: 352 year: 2012 ident: 2022031301280987800_B1 article-title: Bariatric surgery to treat type 2 diabetes: what is the recent evidence publication-title: Curr Opin Endocrinol Diabetes Obes doi: 10.1097/MED.0b013e328357f0e0 – volume: 34 start-page: 1481 year: 2011 ident: 2022031301280987800_B8 article-title: Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc10-2415 – volume: 11 start-page: 361 year: 2009 ident: 2022031301280987800_B77 article-title: Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2008.00970.x – volume: 57 start-page: S8 year: 2014 ident: 2022031301280987800_B64 article-title: Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition publication-title: Diabetologia – volume: 95 start-page: 297 year: 2012 ident: 2022031301280987800_B84 article-title: Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study publication-title: Am J Clin Nutr doi: 10.3945/ajcn.111.024927 – volume: 21 start-page: 27 year: 2015 ident: 2022031301280987800_B104 article-title: A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents publication-title: Nat Med doi: 10.1038/nm.3761 – volume: 97 start-page: 1020 year: 2012 ident: 2022031301280987800_B57 article-title: Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2011-2260 – volume: 5 start-page: 163 year: 2011 ident: 2022031301280987800_B99 article-title: Novel approaches to the treatment of obesity and type 2 diabetes mellitus: bioactive leptin-related synthetic peptide analogs publication-title: Recent Pat Endocr Metab Immune Drug Discov doi: 10.2174/187221411797265917 – ident: 2022031301280987800_B91 – volume: 28 start-page: 1027 year: 2012 ident: 2022031301280987800_B15 article-title: Characterizing and understanding body weight patterns in patients treated with pregabalin publication-title: Curr Med Res Opin doi: 10.1185/03007995.2012.684044 – volume: 365 start-page: 1597 year: 2011 ident: 2022031301280987800_B20 article-title: Long-term persistence of hormonal adaptations to weight loss publication-title: N Engl J Med doi: 10.1056/NEJMoa1105816 – volume: 33 start-page: 1173 year: 2010 ident: 2022031301280987800_B92 article-title: Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes publication-title: Diabetes Care doi: 10.2337/dc09-1203 – volume: 5 start-page: 621 year: 2012 ident: 2022031301280987800_B74 article-title: Anti-obesity drugs: past, present and future publication-title: Dis Model Mech doi: 10.1242/dmm.009621 – volume: 16 start-page: 159 year: 2014 ident: 2022031301280987800_B58 article-title: Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin publication-title: Diabetes Obes Metab doi: 10.1111/dom.12189 – ident: 2022031301280987800_B85 – volume: 27 start-page: 155 year: 2004 ident: 2022031301280987800_B76 article-title: XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients publication-title: Diabetes Care doi: 10.2337/diacare.27.1.155 – volume: 30 start-page: 163 year: 2014 ident: 2022031301280987800_B60 article-title: Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study publication-title: Curr Med Res Opin doi: 10.1185/03007995.2013.850066 – volume: 63 start-page: 1422 year: 2014 ident: 2022031301280987800_B102 article-title: GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet publication-title: Diabetes doi: 10.2337/db13-1609 – volume: 5 start-page: 749 year: 2009 ident: 2022031301280987800_B109 article-title: A new glucagon and GLP-1 co-agonist eliminates obesity in rodents publication-title: Nat Chem Biol doi: 10.1038/nchembio.209 – volume: 363 start-page: 245 year: 2010 ident: 2022031301280987800_B79 article-title: Multicenter, placebo-controlled trial of lorcaserin for weight management publication-title: N Engl J Med doi: 10.1056/NEJMoa0909809 – volume: 12 start-page: 1439 year: 2011 ident: 2022031301280987800_B68 article-title: Pramlintide and the treatment of diabetes: a review of the data since its introduction publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.2011.581663 – volume: 20 start-page: 1426 year: 2012 ident: 2022031301280987800_B71 article-title: Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study publication-title: Obesity (Silver Spring) doi: 10.1038/oby.2012.66 – volume: 9 start-page: 799 year: 2007 ident: 2022031301280987800_B25 article-title: Insulin-associated weight gain in diabetes—causes, effects and coping strategies publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2006.00686.x – volume: 36 start-page: 843 year: 2012 ident: 2022031301280987800_B88 article-title: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide publication-title: Int J Obes (Lond) doi: 10.1038/ijo.2011.158 – volume: 352 start-page: 837 year: 1998 ident: 2022031301280987800_B13 article-title: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) publication-title: Lancet doi: 10.1016/S0140-6736(98)07019-6 – volume: 30 start-page: 1480 year: 2007 ident: 2022031301280987800_B82 article-title: A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients publication-title: Diabetes Care doi: 10.2337/dc06-2001 – volume: 15 start-page: 607 year: 2013 ident: 2022031301280987800_B97 article-title: Leptin therapy in type 2 diabetes publication-title: Diabetes Obes Metab doi: 10.1111/dom.12048 – volume: 55 start-page: 215 year: 2012 ident: 2022031301280987800_B100 article-title: Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C2C12 muscle and AML12 liver cell lines publication-title: Diabetologia doi: 10.1007/s00125-011-2332-0 – ident: 2022031301280987800_B45 – volume: 5 start-page: 262 year: 2009 ident: 2022031301280987800_B98 article-title: Incretin-based therapies for type 2 diabetes mellitus publication-title: Nat Rev Endocrinol doi: 10.1038/nrendo.2009.48 – volume: 27 start-page: 1519 year: 2011 ident: 2022031301280987800_B43 article-title: GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials publication-title: Curr Med Res Opin doi: 10.1185/03007995.2011.590127 – volume: 444 start-page: 875 year: 2006 ident: 2022031301280987800_B2 article-title: Mechanisms linking obesity with cardiovascular disease publication-title: Nature doi: 10.1038/nature05487 – volume: 56 start-page: 841 year: 2008 ident: 2022031301280987800_B37 article-title: Expression of the GLP-1 receptor in mouse, rat, and human pancreas publication-title: J Histochem Cytochem doi: 10.1369/jhc.2008.951319 – ident: 2022031301280987800_B3 – volume: 37 start-page: 3309 year: 2014 ident: 2022031301280987800_B72 article-title: Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release publication-title: Diabetes Care doi: 10.2337/dc14-0930 – volume: 15 start-page: 42 year: 2013 ident: 2022031301280987800_B47 article-title: Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2012.01673.x – volume: 60 start-page: 1272 year: 2006 ident: 2022031301280987800_B34 article-title: Thiazolidinediones, insulin resistance and obesity: finding a balance publication-title: Int J Clin Pract doi: 10.1111/j.1742-1241.2006.01128.x |
RestrictionsOnAccess | restricted access |
SSID | ssj0004488 |
Score | 2.5379667 |
SecondaryResourceType | review_article |
Snippet | Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also... |
SourceID | liege proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1161 |
SubjectTerms | Anti-Obesity Agents - therapeutic use Blood Glucose - metabolism Cardiovascular disease Diabetes Diabetes Mellitus, Type 2 - prevention & control Diabetic Angiopathies - prevention & control Drug Therapy, Combination Endocrinologie, métabolisme & nutrition Endocrinology, metabolism & nutrition Forecasting Human health sciences Humans Hypoglycemic Agents - adverse effects Medical treatment Obesity Obesity - prevention & control Pharmacie, pharmacologie & toxicologie Pharmacy, pharmacology & toxicology Risk Reduction Behavior Sciences de la santé humaine Weight control Weight Gain - drug effects Weight Loss - drug effects |
Title | Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25998297 https://www.proquest.com/docview/1686813906 https://www.proquest.com/docview/1702644605 http://orbi.ulg.ac.be/handle/2268/182310 |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQKyEuiDfbFmQQByQIJLaT2NxWQFnoQzy20JvlxA6ttMqikuXAr2fGzmurgoBLFCWWbc18tmfG8yDkUV5UTrgkjVRpskhUCY-MhOVeMqaKklshDAYKHxxmsyPx7jg9Hqpt-uiSpnhW_rwwruR_uArfgK8YJfsPnO07hQ_wDvyFJ3AYnn_F4y_erjlyYUHrxTwYVVtXF-_x1iVhQiM5WqF8YaJpm0085HiYdw7nY2m168Pnr-5Y8xl2hDfG1wl4sr8qh5uck7bGPfpIhvv3sUkBGNW7Po28-KGzfpTzUOlskSpKlVrbTLkcgWa8MyZJSLp-fstm3Af92zIREciG8XAudXfxs-kn_f7Vrt5_e7i3_jccw3ksQSfKUAfeZKAsYB2LvQ-jnPHCVx_tpxvyS-G4z_tR16SSzQX6K_xe5fCix_waudrqDHQaAHCdXHL1DXL5oPWKuEk-BhzQAQf0tKaIA8poR90XtEUBBRTQDgV0QAFtlrRHwS1ytPt6_nIWtbUyIiNy1US5YUokJjOVKoUtWFVUzOWyxHJwqbG8Yjy3hstKclAoubBpyk2uHLNJbmxq-W2yUS9rd5fQ1GZSGNCjpa1E4ZxyUqaiYMJKOA9MPCGPO1rpsk0kj_VMFhoUSiSrRrJqJOuEPOybfgvZUy5q9NQTXC_PilP9g2nMeO7fV4uv2pS6cBqUBKkTvLKG5jsdX3S7Fr9DPzKToMzE2YQ86H_DTonXX6Z2yxW0yWOU_kF_n5A7gZ_9pBgAA4PMt_7c-Ta5MqyXHbLRnK3cPRBKm-K-x9wvioOK9g |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Weight+Management+in+Type+2+Diabetes%3A+Current+and+Emerging+Approaches+to+Treatment&rft.jtitle=Diabetes+care&rft.au=Van+Gaal%2C+Luc&rft.au=Scheen%2C+Andr%C3%A9&rft.date=2015-06-01&rft.pub=American+Diabetes+Association&rft.issn=0149-5992&rft.volume=38&rft.issue=6&rft.spage=1161&rft_id=info:doi/10.2337%2Fdc14-1630&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=3708747661 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0149-5992&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0149-5992&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0149-5992&client=summon |